​

Arvinas (ARVN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ARVN Stock Forecast

Arvinas (ARVN) stock forecast, based on 20 Wall Street analysts, predicts a 12-month average price target of $41.71, with a high of $69.00 and a low of $12.00. This represents a 445.23% increase from the last price of $7.65.

$5 $18 $31 $44 $57 $70 High: $69 Avg: $41.71 Low: $12 Last Closed Price: $7.65

ARVN Stock Rating

Arvinas stock's rating consensus is Buy, based on 20 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 18 Buy (90.00%), 2 Hold (10.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 20 0 2 18 Strong Sell Sell Hold Buy Strong Buy

ARVN Price Target Upside V Benchmarks

TypeNameUpside
StockArvinas445.23%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts-38
Avg Price Target-$19.33$45.25
Last Closing Price$7.65$7.65$7.65
Upside/Downside-152.68%491.50%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 254135--22
Mar, 255142--21
Feb, 255132--20
Jan, 255152--22
Dec, 245152--22
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 13, 2025Morgan Stanley$12.00$8.5540.35%56.86%
Mar 12, 2025Etzer DaroutBMO Capital$20.00$8.43137.25%161.44%
Mar 12, 2025Derek ArchilaWells Fargo$26.00$8.30213.25%239.87%
Dec 10, 2024Jeet MukherjeeBTIG$69.00$24.59180.60%801.96%
Nov 19, 2024Christopher LiuLeerink Partners$62.00$24.94148.60%710.46%
Oct 31, 2024Matthew BieglerOppenheimer$40.00$27.6644.61%422.88%
Oct 21, 2024Bradley CaninoStifel Nicolaus$63.00$27.11132.39%723.53%
May 16, 2024Matthew BieglerOppenheimer$70.00$32.11118.00%815.03%
Apr 12, 2024Andrew FeinH.C. Wainwright$87.00$37.26133.49%1037.25%
Apr 11, 2024Bradley CaninoStifel Nicolaus$72.00$38.7385.90%841.18%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 12, 2025BMO CapitalOutperformOutperformhold
Mar 12, 2025WedbushBuyNeutraldowngrade
Mar 12, 2025Wells FargoOverweightOverweighthold
Mar 11, 2025CitigroupNeutralNeutralhold
Mar 11, 2025OppenheimerOutperformPerformdowngrade
Dec 10, 2024BTIGBuyinitialise
Nov 19, 2024Leerink PartnersOutperformOutperformhold
Oct 31, 2024OppenheimerOutperformOutperformhold
Sep 09, 2024WedbushBuyBuyhold
Jul 31, 2024Wells FargoBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.83$-3.66$-5.11$-6.62$-2.77----
Avg Forecast$-2.76$-3.56$-4.94$-5.11$-3.15$-4.69$-4.51$-2.96$-1.22
High Forecast$-1.60$-2.06$-2.87$-4.56$-2.31$-2.93$0.94$2.52$-0.54
Low Forecast$-4.57$-5.89$-8.15$-5.68$-4.35$-8.05$-8.16$-7.26$-2.27
Surprise %2.54%2.81%3.44%29.55%-12.06%----

Revenue Forecast

$0 $190M $380M $570M $760M $950M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$21.80M$46.70M$131.40M$78.50M$263.40M----
Avg Forecast$26.24M$74.13M$120.80M$168.51M$264.73M$214.45M$252.55M$358.29M$548.04M
High Forecast$39.44M$111.40M$181.27M$197.30M$323.20M$341.08M$254.75M$363.26M$910.60M
Low Forecast$17.75M$50.15M$81.88M$152.61M$232.71M$123.45M$250.35M$353.32M$311.26M
Surprise %-16.92%-37.00%8.78%-53.42%-0.50%----

Net Income Forecast

$-500M $-370M $-240M $-110M $20M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-111.79M$-183.20M$-271.90M$-367.30M$-198.90M----
Avg Forecast$-153.36M$-215.82M$-220.51M$-367.30M$-184.72M$-341.42M$-363.59M$-282.85M$-67.88M
High Forecast$-88.87M$-172.65M$-176.41M$-293.84M$-128.03M$-162.87M$51.90M$139.59M$-29.75M
Low Forecast$-253.61M$-258.98M$-264.61M$-440.76M$-241.41M$-446.89M$-452.74M$-402.83M$-126.25M
Surprise %-27.11%-15.11%23.31%-7.68%----

ARVN Forecast FAQ

Is Arvinas stock a buy?

Arvinas stock has a consensus rating of Buy, based on 20 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 18 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Arvinas is a favorable investment for most analysts.

What is Arvinas's price target?

Arvinas's price target, set by 20 Wall Street analysts, averages $41.71 over the next 12 months. The price target range spans from $12 at the low end to $69 at the high end, suggesting a potential 445.23% change from the previous closing price of $7.65.

How does Arvinas stock forecast compare to its benchmarks?

Arvinas's stock forecast shows a 445.23% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Arvinas over the past three months?

  • April 2025: 18.18% Strong Buy, 59.09% Buy, 22.73% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 23.81% Strong Buy, 66.67% Buy, 9.52% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 25.00% Strong Buy, 65.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.

What is Arvinas’s EPS forecast?

Arvinas's average annual EPS forecast for its fiscal year ending in December 2025 is $-4.69, marking a 69.31% increase from the reported $-2.77 in 2024. Estimates for the following years are $-4.51 in 2026, $-2.96 in 2027, and $-1.22 in 2028.

What is Arvinas’s revenue forecast?

Arvinas's average annual revenue forecast for its fiscal year ending in December 2025 is $214.45M, reflecting a -18.58% decrease from the reported $263.4M in 2024. The forecast for 2026 is $252.55M, followed by $358.29M for 2027, and $548.04M for 2028.

What is Arvinas’s net income forecast?

Arvinas's net income forecast for the fiscal year ending in December 2025 stands at $-341M, representing an 71.66% increase from the reported $-199M in 2024. Projections indicate $-364M in 2026, $-283M in 2027, and $-67.877M in 2028.